Streetbeat News

SHPH

Shuttle Pharmaceuticals Holdings, Inc.

https://www.shuttlepharma.com

Industry

Drug Manufacturers - Specialty & Generic

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Open

1.18

Mkt cap

3.9M

Volume

80K

High

1.19

P/E Ratio

-0.33

52-wk high

4.94

Low

1.15

Div yield

N/A

52-wk low

1.03

VF Corp shares surged 21.4% in pre-market trading after reporting better-than-expected Q2 results, with revenue of $2.8 billion and earnings of 60 cents per share. Other stocks like Shuttle Pharmaceuticals and Lixte Biotechnology also saw significant pre-market gains.

Portfolio Pulse from Avi Kapoor

October 29, 2024 | 10:12 am

In Monday's after-market session, Shuttle Pharmaceuticals, Impact BioMedical, and Onconetix saw significant stock price increases, while TransMedics Group and Cardio Diagnostics Holdings experienced notable declines. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 8:31 pm

Shuttle Pharmaceuticals shares rose as the company finalized agreements with six sites for the Phase 2 clinical trial of Ropidoxuridine.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 8:24 pm

Shuttle Pharma has finalized agreements with six sites for a Phase 2 clinical trial of Ropidoxuridine, a radiation sensitizer for glioblastoma treatment. The drug has received Orphan Drug Designation from the FDA, which could provide marketing exclusivity upon approval.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 8:10 pm

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Tempest Therapeutics, and Portage Biotech, while Gritstone Bio and 10x Genomics were among the major losers.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:08 pm

In Tuesday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Inspire Veterinary, CASI Pharmaceuticals, and Shuttle Pharmaceuticals, while Nuwellis, Puma Biotechnology, and Agape ATP were among the losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 8:31 pm

Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment to two additional sites, totaling four centers ready for patient enrollment. The participating centers are UVA Cancer Center, John Theurer Cancer Center, AHN Cancer Institute, and Miami Cancer Institute.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:03 pm

Shuttle Pharmaceuticals (SHPH) shares experienced significant volatility, initially rising by 44% in pre-market trading before falling by 1.69% to $2.33. This movement followed the announcement of a new U.S. patent for selective histone deacetylase inhibitors, which are being developed for cancer and other diseases.

Portfolio Pulse from Henry Khederian

September 05, 2024 | 3:18 pm

Shuttle Pharmaceuticals shares rose following the issuance of a new U.S. patent for their selective histone deacetylase inhibitors, which are used in treating human diseases.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 1:07 pm

Shuttle Pharma has been granted a U.S. patent for its selective histone deacetylase inhibitors, which are used in the treatment of human diseases. This development could enhance the company's intellectual property portfolio and potentially lead to new therapeutic applications.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.